Nurix Therapeutics Hits New 52-Week High of $23.09, Up 46.61%

Nurix Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 23.09 on June 25, 2026. This achievement marks a notable increase from its 52-week low of USD 8.20, reflecting a robust performance over the past year with a gain of 46.61%. The company's market capitalization stands at approximately USD 1,518 million, positioning it firmly within the small-cap category. Despite its recent price surge, Nurix Therapeutics remains a loss-making entity, as indicated by its non-applicable price-to-earnings (P/E) ratio. The company does not offer a dividend, and its debt-to-equity ratio is reported at -1.10, suggesting a unique financial structure. Additionally, the return on equity is at -49.09%, and the price-to-book ratio is 2.82, providing insight into its valuation relative to its assets. This recent price movement underscores the dynamic nature of Nurix Therapeutics within the competitive landscape of the biotechnology industry.